RxDoctor Payments Data

Opeyemi Olabisi, MD

Internal Medicine · Boston, MANPI 1104052612

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,945 of the $4,859 with a category attached, or 60.6%. Regeneron accounts for 87.4% of it on its own, with 1 other manufacturer making up the rest. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,859in general payments, 2019–2025

Across 17 payments — averaging $285.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$4K
  • Vertex$614
$125,541in research payments, 2019–2025

Across 10 payments — averaging $12,554 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$126K

What the payments were for

  • Consulting fees$1,71335%
  • Travel & lodging$2,94561%
  • Food & beverage$2004%

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron12$4,245
Vertex5$614

How this compares

$4,859 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$9,688
Medicare patients
35
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →